Stifel Financial Corp Grows Stock Holdings in argenx SE (NASDAQ:ARGX)

Stifel Financial Corp lifted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 15.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,832 shares of the company's stock after acquiring an additional 1,170 shares during the period. Stifel Financial Corp's holdings in argenx were worth $4,788,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ARGX. Profund Advisors LLC increased its position in shares of argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock worth $418,000 after purchasing an additional 28 shares during the last quarter. Raymond James Trust N.A. boosted its stake in shares of argenx by 6.0% in the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock valued at $268,000 after purchasing an additional 28 shares in the last quarter. Wealth Alliance grew its holdings in shares of argenx by 4.8% during the 2nd quarter. Wealth Alliance now owns 628 shares of the company's stock valued at $270,000 after purchasing an additional 29 shares during the last quarter. Hantz Financial Services Inc. raised its position in argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company's stock worth $286,000 after purchasing an additional 43 shares during the period. Finally, GAMMA Investing LLC lifted its stake in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after purchasing an additional 56 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX traded up $25.43 during midday trading on Monday, hitting $632.64. The company had a trading volume of 222,159 shares, compared to its average volume of 307,781. The company has a market cap of $38.19 billion, a price-to-earnings ratio of -718.91 and a beta of 0.59. argenx SE has a 12-month low of $327.73 and a 12-month high of $643.63. The company has a fifty day moving average of $583.23 and a two-hundred day moving average of $517.38.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the business posted ($1.25) EPS. Research analysts expect that argenx SE will post 2.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ARGX shares. HC Wainwright reiterated a "buy" rating and issued a $617.00 price objective on shares of argenx in a report on Wednesday, November 20th. Wedbush reissued an "outperform" rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. Wells Fargo & Company increased their price target on shares of argenx from $547.00 to $639.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Evercore ISI upped their price objective on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. Finally, Oppenheimer reissued an "outperform" rating and issued a $675.00 target price (up from $646.00) on shares of argenx in a research note on Thursday, November 21st. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $635.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.